Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial

AI Summary

A late-stage melanoma clinical trial combining personalized cancer vaccines from Moderna and Merck showed significant promise by extending the remission period compared to treatments with Keytruda alone. This advancement could improve melanoma patient outcomes significantly.

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.